medical supply

An analyst at Morgan Stanley is impressed with the device pipeline at Abbott Laboratories (NYSE: ABT). The Analyst Morgan Stanley analyst David Lewis upgraded shares of Abbott Labs from Equal-Weight to Overweight and lifted the price target from $60 to $67. The Thesis Abbott Lab's...

Medtronic PLC (NYSE: MDT) is poised for better opportunities ahead after a long period of underperformance, Argus said in a Tuesday note. The firm noted that shares of Medtronic have underperformed the broader market over the past three months, adding 1.9 percent compared to the S&P 500's 6...